- Home
- OTLK vs CULP Comparison
OTLK vs CULP Comparison
Compare OTLK & CULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CULP
- Stock Information
- Founded
- OTLK 2010
- CULP 1972
- Country
- OTLK United States
- CULP United States
- Employees
- OTLK N/A
- CULP N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CULP Textiles
- Sector
- OTLK Health Care
- CULP Consumer Discretionary
- Exchange
- OTLK Nasdaq
- CULP Nasdaq
- Market Cap
- OTLK 48.3M
- CULP 50.9M
- IPO Year
- OTLK 2016
- CULP N/A
- Fundamental
- Price
- OTLK $1.57
- CULP $3.96
- Analyst Decision
- OTLK Strong Buy
- CULP
- Analyst Count
- OTLK 5
- CULP 0
- Target Price
- OTLK $9.60
- CULP N/A
- AVG Volume (30 Days)
- OTLK 796.7K
- CULP 17.2K
- Earning Date
- OTLK 08-13-2025
- CULP 06-25-2025
- Dividend Yield
- OTLK N/A
- CULP N/A
- EPS Growth
- OTLK N/A
- CULP N/A
- EPS
- OTLK 0.83
- CULP N/A
- Revenue
- OTLK N/A
- CULP $213,237,000.00
- Revenue This Year
- OTLK N/A
- CULP N/A
- Revenue Next Year
- OTLK $379.84
- CULP $5.99
- P/E Ratio
- OTLK $1.91
- CULP N/A
- Revenue Growth
- OTLK N/A
- CULP N/A
- 52 Week Low
- OTLK $0.87
- CULP $3.42
- 52 Week High
- OTLK $9.25
- CULP $6.85
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- CULP 46.36
- Support Level
- OTLK $1.65
- CULP $3.76
- Resistance Level
- OTLK $2.04
- CULP $4.03
- Average True Range (ATR)
- OTLK 0.12
- CULP 0.19
- MACD
- OTLK -0.03
- CULP 0.00
- Stochastic Oscillator
- OTLK 2.13
- CULP 48.65
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CULP Culp Inc.
Culp Inc manufactures, sources, and markets mattress fabrics and sewn covers used for covering mattresses and box springs and upholstery fabrics including cut and sewn kits used in the production of upholstered furniture. The company has two operating segments Mattress fabrics which generates maximum revenue, and Upholstery fabrics. The mattress fabrics segment, also known as Culp Home Fashions, manufactures and markets mattress fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment markets fabrics for residential, commercial, and hospitality furniture and also provides window treatment products and installation services for its customers in the hospitality and commercial industries. Geographically, it derives key revenue from the United States of America.